CRISPR Therapeutics AG — Director's Dealing 2019

Dec 2, 2019

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: CRISPR Therapeutics AG (CRSP)
CIK: 0001674416
Period of Report: 2019-12-01

Reporting Person: Kulkarni Samarth (Director, Chief Executive Officer)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2019-12-01	Common Shares	F	741	$71.65	Disposed	164320	Direct

Footnotes

F1: On December 1, 2017, the reporting person was granted 26,667 restricted stock units. On December 1, 2019, 1,667 restricted stock units vested, and the reporting person forfeited 741 common shares to the issuer to satisfy tax withholding obligations.